<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36717723</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1529-2916</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Nature immunology</Title><ISOAbbreviation>Nat Immunol</ISOAbbreviation></Journal><ArticleTitle>A patient-centric modeling framework captures recovery from SARS-CoV-2 infection.</ArticleTitle><Pagination><StartPage>349</StartPage><EndPage>358</EndPage><MedlinePgn>349-358</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41590-022-01380-2</ELocationID><Abstract><AbstractText>The biology driving individual patient responses to severe acute respiratory syndrome coronavirus 2 infection remains ill understood. Here, we developed a patient-centric framework leveraging detailed longitudinal phenotyping data and covering a year after disease onset, from 215 infected individuals with differing disease severities. Our analyses revealed distinct 'systemic recovery' profiles, with specific progression and resolution of the inflammatory, immune cell, metabolic and clinical responses. In particular, we found a strong inter-patient and intra-patient temporal covariation of innate immune cell numbers, kynurenine metabolites and lipid metabolites, which highlighted candidate immunologic and metabolic pathways influencing the restoration of homeostasis, the risk of death and that of long COVID. Based on these data, we identified a composite signature predictive of systemic recovery, using a joint model on cellular and molecular parameters measured soon after disease onset. New predictions can be generated using the online tool http://shiny.mrc-bsu.cam.ac.uk/apps/covid-19-systemic-recovery-prediction-app , designed to test our findings prospectively.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ruffieux</LastName><ForeName>H&#xe9;l&#xe8;ne</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-7113-2540</Identifier><AffiliationInfo><Affiliation>MRC Biostatistics Unit, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK. helene.ruffieux@mrc-bsu.cam.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanson</LastName><ForeName>Aimee L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lodge</LastName><ForeName>Samantha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Australian National Phenome Centre, Health Futures Institute, Murdoch University, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Computational and Systems Medicine, Health Futures Institute, Murdoch University, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lawler</LastName><ForeName>Nathan G</ForeName><Initials>NG</Initials><Identifier Source="ORCID">0000-0001-9649-425X</Identifier><AffiliationInfo><Affiliation>Australian National Phenome Centre, Health Futures Institute, Murdoch University, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Computational and Systems Medicine, Health Futures Institute, Murdoch University, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whiley</LastName><ForeName>Luke</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Australian National Phenome Centre, Health Futures Institute, Murdoch University, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Computational and Systems Medicine, Health Futures Institute, Murdoch University, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Perron Institute for Neurological and Translational Science, Nedlands, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gray</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-0094-5245</Identifier><AffiliationInfo><Affiliation>Australian National Phenome Centre, Health Futures Institute, Murdoch University, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Computational and Systems Medicine, Health Futures Institute, Murdoch University, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nolan</LastName><ForeName>Tui H</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>MRC Biostatistics Unit, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bergamaschi</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mescia</LastName><ForeName>Federica</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-2759-4027</Identifier><AffiliationInfo><Affiliation>Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Lorinda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Sa</LastName><ForeName>Aloka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pelly</LastName><ForeName>Victoria S</ForeName><Initials>VS</Initials><AffiliationInfo><Affiliation>Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Cambridge Institute of Therapeutic Immunology and Infectious Disease-National Institute of Health Research (CITIID-NIHR) BioResource COVID-19 Collaboration</CollectiveName></Author><Author ValidYN="Y"><LastName>Kotagiri</LastName><ForeName>Prasanti</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-9806-4349</Identifier><AffiliationInfo><Affiliation>Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kingston</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR BioResource, Cambridge University Hospitals NHS Foundation, Cambridge Biomedical Campus, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bradley</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR BioResource, Cambridge University Hospitals NHS Foundation, Cambridge Biomedical Campus, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>Elaine</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-0556-8389</Identifier><AffiliationInfo><Affiliation>Australian National Phenome Centre, Health Futures Institute, Murdoch University, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Computational and Systems Medicine, Health Futures Institute, Murdoch University, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wist</LastName><ForeName>Julien</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3416-2572</Identifier><AffiliationInfo><Affiliation>Australian National Phenome Centre, Health Futures Institute, Murdoch University, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Computational and Systems Medicine, Health Futures Institute, Murdoch University, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chemistry Department, Universidad del Valle, Cali, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicholson</LastName><ForeName>Jeremy K</ForeName><Initials>JK</Initials><Identifier Source="ORCID">0000-0002-8123-8349</Identifier><AffiliationInfo><Affiliation>Australian National Phenome Centre, Health Futures Institute, Murdoch University, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Computational and Systems Medicine, Health Futures Institute, Murdoch University, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Global Health Innovation, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyons</LastName><ForeName>Paul A</ForeName><Initials>PA</Initials><Identifier Source="ORCID">0000-0001-7035-8997</Identifier><AffiliationInfo><Affiliation>Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Kenneth G C</ForeName><Initials>KGC</Initials><AffiliationInfo><Affiliation>Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richardson</LastName><ForeName>Sylvia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1998-492X</Identifier><AffiliationInfo><Affiliation>MRC Biostatistics Unit, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bantug</LastName><ForeName>Glenn R</ForeName><Initials>GR</Initials><Identifier Source="ORCID">0000-0003-2253-6028</Identifier><AffiliationInfo><Affiliation>Department of Biomedicine, University and University Hospital Basel, Basel, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Botnar Research Centre for Child Health (BRCCH) University Basel &amp; ETH Zurich, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hess</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-0364-8825</Identifier><AffiliationInfo><Affiliation>Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK. ch818@cam.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK. ch818@cam.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedicine, University and University Hospital Basel, Basel, Switzerland. ch818@cam.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Botnar Research Centre for Child Health (BRCCH) University Basel &amp; ETH Zurich, Basel, Switzerland. ch818@cam.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>219506/Z/19/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L019027</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L019027/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>200871/Z/16/ Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>200871</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>200871/Z/16/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Immunol</MedlineTA><NlmUniqueID>100941354</NlmUniqueID><ISSNLinking>1529-2908</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>343-65-7</RegistryNumber><NameOfSubstance UI="D007737">Kynurenine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Immunol. 2023 Feb;24(2):207-208. doi: 10.1038/s41590-022-01396-8</RefSource><PMID Version="1">36717724</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007737" MajorTopicYN="N">Kynurenine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018802" MajorTopicYN="N">Patient-Centered Care</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>30</Day><Hour>23</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36717723</ArticleId><ArticleId IdType="pmc">PMC9892000</ArticleId><ArticleId IdType="doi">10.1038/s41590-022-01380-2</ArticleId><ArticleId IdType="pii">10.1038/s41590-022-01380-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>ReliefWeb. Coronavirus Disease (COVID-19): Weekly Epidemiological Update (4 January 2023)&#x2014;World https://reliefweb.int/report/world/coronavirus-disease-covid-19-weekly-epidemiological-update-4-january-2023</Citation></Reference><Reference><Citation>Alwan NA. Track COVID-19 sickness, not just positive tests and deaths. Nature. 2020;584:170. doi: 10.1038/d41586-020-02335-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-020-02335-z</ArticleId><ArticleId IdType="pubmed">32782377</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220&#x2013;232. doi: 10.1016/S0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, et al. Attributes and predictors of long COVID. Nat. Med. 2021;27:626&#x2013;631. doi: 10.1038/s41591-021-01292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas C, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020;584:463&#x2013;469. doi: 10.1038/s41586-020-2588-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2588-y</ArticleId><ArticleId IdType="pmc">PMC7477538</ArticleId><ArticleId IdType="pubmed">32717743</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda R, et al. Integrative modeling of plasma metabolic and lipoprotein biomarkers of SARS-CoV-2 infection in Spanish and Australian COVID-19 patient cohorts. J. Proteome Res. 2021;20:4139&#x2013;4152. doi: 10.1021/acs.jproteome.1c00458.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.1c00458</ArticleId><ArticleId IdType="pubmed">34251833</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes E, et al. Incomplete systemic recovery and metabolic phenoreversion in post-acute-phase nonhospitalized COVID-19 patients: implications for assessment of post-acute COVID-19 syndrome. J. Proteome Res. 2021;20:3315&#x2013;3329. doi: 10.1021/acs.jproteome.1c00224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.1c00224</ArticleId><ArticleId IdType="pubmed">34009992</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, et al. Markers of Immune activation and inflammation in individuals with postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. J. Infect. Dis. 2021;224:1839&#x2013;1848. doi: 10.1093/infdis/jiab490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab490</ArticleId><ArticleId IdType="pmc">PMC8643408</ArticleId><ArticleId IdType="pubmed">34677601</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergamaschi L, et al. Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. Immunity. 2021;54:1257&#x2013;1275. doi: 10.1016/j.immuni.2021.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.05.010</ArticleId><ArticleId IdType="pmc">PMC8125900</ArticleId><ArticleId IdType="pubmed">34051148</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner-Stokes L, et al. The post-ICU presentation screen (PICUPS) and rehabilitation prescription (RP) for intensive care survivors part I: development and preliminary clinimetric evaluation. J. Intensive Care Soc. 2022;23:253&#x2013;263. doi: 10.1177/1751143720988715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1751143720988715</ArticleId><ArticleId IdType="pmc">PMC9411778</ArticleId><ArticleId IdType="pubmed">36033253</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W, et al. Plasma CRP level is positively associated with the severity of COVID-19. Ann. Clin. Microbiol. Antimicrob. 2020;19:18. doi: 10.1186/s12941-020-00362-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12941-020-00362-2</ArticleId><ArticleId IdType="pmc">PMC7227180</ArticleId><ArticleId IdType="pubmed">32414383</ArticleId></ArticleIdList></Reference><Reference><Citation>Herold T, et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J. Allergy Clin. Immunol. 2020;146:128&#x2013;136. doi: 10.1016/j.jaci.2020.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.05.008</ArticleId><ArticleId IdType="pmc">PMC7233239</ArticleId><ArticleId IdType="pubmed">32425269</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvan ME. Risk factors for death from COVID-19. Nat. Rev. Immunol. 2020;20:407&#x2013;407. doi: 10.1038/s41577-020-0351-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0351-0</ArticleId><ArticleId IdType="pmc">PMC7251559</ArticleId><ArticleId IdType="pubmed">32461673</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawler NG, et al. Systemic perturbations in amine and kynurenine metabolism associated with acute SARS-CoV-2 infection and inflammatory cytokine responses. J. Proteome Res. 2021;20:2796&#x2013;2811. doi: 10.1021/acs.jproteome.1c00052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.1c00052</ArticleId><ArticleId IdType="pubmed">33724837</ArticleId></ArticleIdList></Reference><Reference><Citation>Buyse S, et al. Critical care management of patients with hemophagocytic lymphohistiocytosis. Intensive Care Med. 2010;36:1695&#x2013;1702. doi: 10.1007/s00134-010-1936-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-010-1936-z</ArticleId><ArticleId IdType="pubmed">20532477</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed F, Jo D-H, Lee S-H. Can natural killer cells be a principal player in anti-SARS-CoV-2 immunity? Front. Immunol. 2020;11:586765. doi: 10.3389/fimmu.2020.586765.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.586765</ArticleId><ArticleId IdType="pmc">PMC7750385</ArticleId><ArticleId IdType="pubmed">33365027</ArticleId></ArticleIdList></Reference><Reference><Citation>Maucourant C, et al. Natural killer cell immunotypes related to COVID-19 disease severity. Sci. Immunol. 2020;5:eabd6832. doi: 10.1126/sciimmunol.abd6832.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abd6832</ArticleId><ArticleId IdType="pmc">PMC7665314</ArticleId><ArticleId IdType="pubmed">32826343</ArticleId></ArticleIdList></Reference><Reference><Citation>Leem G, et al. Abnormality in the NK-cell population is prolonged in severe COVID-19 patients. J. Allergy Clin. Immunol. 2021;148:996&#x2013;1006. doi: 10.1016/j.jaci.2021.07.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2021.07.022</ArticleId><ArticleId IdType="pmc">PMC8324384</ArticleId><ArticleId IdType="pubmed">34339730</ArticleId></ArticleIdList></Reference><Reference><Citation>Witkowski M, et al. Untimely TGF-&#x3b2; responses in COVID-19 limit antiviral functions of NK cells. Nature. 2021;600:295&#x2013;301. doi: 10.1038/s41586-021-04142-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04142-6</ArticleId><ArticleId IdType="pubmed">34695836</ArticleId></ArticleIdList></Reference><Reference><Citation>Correale J. Immunosuppressive amino-acid catabolizing enzymes in multiple sclerosis. Front. Immunol. 2021;11:600428. doi: 10.3389/fimmu.2020.600428.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.600428</ArticleId><ArticleId IdType="pmc">PMC7855700</ArticleId><ArticleId IdType="pubmed">33552055</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone TW. Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection. Trends Pharmacol. Sci. 2000;21:149&#x2013;154. doi: 10.1016/S0165-6147(00)01451-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-6147(00)01451-6</ArticleId><ArticleId IdType="pubmed">10740291</ArticleId></ArticleIdList></Reference><Reference><Citation>Remus JL, Dantzer R. Inflammation models of depression in rodents: relevance to psychotropic drug discovery. Int. J. Neuropsychopharmacol. 2016;19:pyw028. doi: 10.1093/ijnp/pyw028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ijnp/pyw028</ArticleId><ArticleId IdType="pmc">PMC5043641</ArticleId><ArticleId IdType="pubmed">27026361</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain. Behav. Immun. 2020;87:18&#x2013;22. doi: 10.1016/j.bbi.2020.03.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.03.031</ArticleId><ArticleId IdType="pmc">PMC7146689</ArticleId><ArticleId IdType="pubmed">32240762</ArticleId></ArticleIdList></Reference><Reference><Citation>Quintana FJ, et al. Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor. Nature. 2008;453:65&#x2013;71. doi: 10.1038/nature06880.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature06880</ArticleId><ArticleId IdType="pubmed">18362915</ArticleId></ArticleIdList></Reference><Reference><Citation>Veldhoen M, et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature. 2008;453:106&#x2013;109. doi: 10.1038/nature06881.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature06881</ArticleId><ArticleId IdType="pubmed">18362914</ArticleId></ArticleIdList></Reference><Reference><Citation>Mezrich JD, et al. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J. Immunol. 2010;185:3190&#x2013;3198. doi: 10.4049/jimmunol.0903670.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0903670</ArticleId><ArticleId IdType="pmc">PMC2952546</ArticleId><ArticleId IdType="pubmed">20720200</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Y, et al. IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell responses in experimental autoimmune encephalomyelitis. J. Immunol. 2010;185:5953&#x2013;5961. doi: 10.4049/jimmunol.1001628.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1001628</ArticleId><ArticleId IdType="pmc">PMC2998795</ArticleId><ArticleId IdType="pubmed">20944000</ArticleId></ArticleIdList></Reference><Reference><Citation>Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. Nat. Med. 2022;28:911&#x2013;923. doi: 10.1038/s41591-022-01810-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01810-6</ArticleId><ArticleId IdType="pubmed">35585196</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881&#x2013;895. doi: 10.1016/j.cell.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Jim&#xe9;nez B, et al. Quantitative lipoprotein subclass and low molecular weight metabolite analysis in human serum and plasma by 1H NMR spectroscopy in a multilaboratory trial. Anal. Chem. 2018;90:11962&#x2013;11971. doi: 10.1021/acs.analchem.8b02412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.analchem.8b02412</ArticleId><ArticleId IdType="pubmed">30211542</ArticleId></ArticleIdList></Reference><Reference><Citation>Loo RL, et al. Quantitative in vitro diagnostic NMR spectroscopy for lipoprotein and metabolite measurements in plasma and serum: recommendations for analytical artifact minimization with special reference to COVID-19/SARS-CoV-2 samples. J. Proteome Res. 2020;19:4428&#x2013;4441. doi: 10.1021/acs.jproteome.0c00537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.0c00537</ArticleId><ArticleId IdType="pubmed">32852212</ArticleId></ArticleIdList></Reference><Reference><Citation>Dona AC, et al. Precision high-throughput proton nmr spectroscopy of human urine, serum, and plasma for large-scale metabolic phenotyping. Anal. Chem. 2014;86:9887&#x2013;9894. doi: 10.1021/ac5025039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ac5025039</ArticleId><ArticleId IdType="pubmed">25180432</ArticleId></ArticleIdList></Reference><Reference><Citation>Lodge S, et al. Diffusion and relaxation edited proton NMR spectroscopy of plasma reveals a high-fidelity supramolecular biomarker signature of SARS-CoV-2 infection. Anal. Chem. 2021;93:3976&#x2013;3986. doi: 10.1021/acs.analchem.0c04952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.analchem.0c04952</ArticleId><ArticleId IdType="pubmed">33577736</ArticleId></ArticleIdList></Reference><Reference><Citation>Akoka S, Barantin L, Trierweiler M. Concentration measurement by proton NMR using the ERETIC method. Anal. Chem. 1999;71:2554&#x2013;2557. doi: 10.1021/ac981422i.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ac981422i</ArticleId><ArticleId IdType="pubmed">21662801</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray N, et al. A simultaneous exploratory and quantitative amino acid and biogenic amine metabolic profiling platform for rapid disease phenotyping via UPLC&#x2013;QToF&#x2013;MS. Talanta. 2021;223:121872. doi: 10.1016/j.talanta.2020.121872.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.talanta.2020.121872</ArticleId><ArticleId IdType="pubmed">33298292</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiley L, et al. Ultrahigh-performance liquid chromatography tandem mass spectrometry with electrospray ionization quantification of tryptophan metabolites and markers of gut health in serum and plasma&#x2014;application to clinical and epidemiology cohorts. Anal. Chem. 2019;91:5207&#x2013;5216. doi: 10.1021/acs.analchem.8b05884.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.analchem.8b05884</ArticleId><ArticleId IdType="pmc">PMC6503468</ArticleId><ArticleId IdType="pubmed">30848589</ArticleId></ArticleIdList></Reference><Reference><Citation>R Software. The R Project for Statistical Computing. https://www.r-project.org/</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao L, Li C, Checkley W, Crainiceanu C. Fast covariance estimation for sparse functional data. Stat. Comput. 2018;28:511&#x2013;522. doi: 10.1007/s11222-017-9744-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11222-017-9744-8</ArticleId><ArticleId IdType="pmc">PMC5807553</ArticleId><ArticleId IdType="pubmed">29449762</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Xiao L, Luo S. Fast covariance estimation for multivariate sparse functional data. Stat. 2020;9:e245. doi: 10.1002/sta4.245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sta4.245</ArticleId><ArticleId IdType="pmc">PMC8276768</ArticleId><ArticleId IdType="pubmed">34262756</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh A, et al. DIABLO: an integrative approach for identifying key molecular drivers from multi-omics assays. Bioinformatics. 2019;35:3055&#x2013;3062. doi: 10.1093/bioinformatics/bty1054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bty1054</ArticleId><ArticleId IdType="pmc">PMC6735831</ArticleId><ArticleId IdType="pubmed">30657866</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>